Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6736 to 6750 of 7669 results

  1. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued [GID-TA10099]

    Technology appraisal guidance
    Discontinued

  2. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued [GID-TA10306]

    Technology appraisal guidance
    Discontinued

  3. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development [GID-TA11022] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. The MAGEC system for spinal lengthening in children with scoliosis (MT169)

    Discontinued [GID-MT544]

    Medical technologies guidance
    Discontinued

  5. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued [GID-TAG433]

    Technology appraisal guidance
    Discontinued

  6. Diabetic foot ulcers - new treatments [ID381]

    Discontinued [GID-TAG371]

    Technology appraisal guidance
    Discontinued

  7. Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

    In development [GID-TA10696] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]

    In development [GID-TA10766] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Glaucoma - lerdelimumab (CAT-152) [ID383]

    In development [GID-TAG381] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]

    In development [GID-TA10995] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    In development [GID-TA11004] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued [GID-TAG417]

    Technology appraisal guidance
    Discontinued

  13. Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

    Discontinued [GID-TA10429]

    Technology appraisal guidance
    Discontinued

  14. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued [GID-TAG511]

    Technology appraisal guidance
    Discontinued

  15. Macular oedema (diabetic) - pegaptanib sodium [ID452]

    Discontinued [GID-TAG280]

    Technology appraisal guidance
    Discontinued